ASX ANNOUNCEMENT
29 November 2018

2018 Annual General Meeting

Melbourne, Australia; 29 November 2018: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company") is pleased to release the attached slide show presentation which will be delivered by its Interim Chief Executive Officer, Dr Paul Kasian, at the Company's 2018 Annual General Meeting to be held at approximately 10.30 am this morning at 60-66 Hanover Street, Fitzroy, Victoria, Australia.

FOR FURTHER INFORMATION PLEASE CONTACT

Dr Paul Kasian
Chairman and Interim CEO
Genetic Technologies Limited
+ 61 3 8412 7000

Jason Wong (USA)
Blueprint Life Science Group
+1 (415) 375 3340, Ext. 4

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company embracing blockchain technologies across Genomic testing platforms. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company's lead product, BREVAGen*plus*®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. For more information, please visit www.brevagenplus.com and www.phenogensciences.com.

Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.



GENETIC TECHNOLOGIES LIMITED

DISEASE RISK ASSESSMENT ON A GLOBAL SCALE

Forward Looking Statements

This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance of Genetic Technologies Limited and certain of the plans and objectives of its management. These statements are statements that are not historical facts.

Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Genetic Technologies Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Genetic Technologies’ current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.

Global healthcare spending is expected to reach $8.7 trillion by 2020.

Chronic disease accounts for 84% of healthcare spending.

By 2020, 50 percent of global health care expenditures will be spent on these diseases:

- Cancer
- Cardiovascular
- Respiratory

The number of diabetes sufferers globally is expected to rise from 415 million to 642 million by 2040.

Chronic disease is fueled by:

- Urbanization
- Sedentary lifestyles
- Changing diets

https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-hc-outlook-2018.pdf



Targeted screening reduces the cost of healthcare.

Early detection reduces the need for expensive, late-stage care.

Limited screening resources can be targeted to those at increased risk.

Our flagship test, BREVAGen*plus*®, predicts a woman's risk of developing breast cancer.

BREVAGen*plus*® allows providers to target limited resources to women who are most likely to develop breast cancer.

- Screening
- Medication
- Lifestyle

Additional screening tests are in development.

Respected collaborators accelerate development.

The University of Melbourne is Australia's peak research university. Our collaboration with Professor John Hopper led to our NHMRC Grant. The National Health and Medical Research Council is Australia's peak funding body for medical research.

Genetic Technologies Announces Grant from NHMRC Awarded to University of Melbourne to Substantially Improve Breast Cancer Risk Prediction and Increase Accessibility

Globe Newswire 1-May-2018 5:30 AM

MELBOURNE, Australia, May 01, 2018 (GLOBE NEWSWIRE) -- Ge
Limited (ASX:GTG) (NASDAQ:GENE↗) ("Company"), a diversified
company embracing blockchain technologies across genomic
pleased to announce the award of an NHMRC Partnership Grant
by Professor John Hopper from the Centre for Epidemio
Melbourne School of Population & Global Health at The University

Ohio State University

Ohio State University operates a clinical genetics service and is a leader in predictive genetic research for breast cancer. GTG is collaborating with Amanda Toland, Director of Clinical Genetics and a leader in the field of genetic risk for breast cancer. Together, we are exploring polygenic risk as a means to more informed decision-making for women with BRCA mutations.

Healthy China 2030

- Comprehensive healthcare plan for 1.5 billion people
  - Disease prevention to control costs
- GTG genetic tests predict an individual's risk of developing disease.
  - Healthcare resources directed to people most at risk.
  - Early intervention and less costly treatment.

Hainan Medical Pilot Zone

- Part of the Hainan Free Trade Zone Initiative
- Allows foreign companies to safely introduce IP and repatriate profits

Through our partnership with Zishan Health, GTG has been invited to participate.

Hainan Medical Pilot Zone

- Part of the Hainan Free Trade Zone Initiative
- Allows foreign companies to safely introduce IP and repatriate profits

Through our partnership with Zishan Health, GTG has been invited to participate.

Zishan Health Consultancy

- Fast-track access to the Chinese FDA
- Connections into the Chinese healthcare sector
- Track record of introducing non-Chinese companies into the Hainan Free Trade Zone
- In-country sales and marketing, both in Hainan and other provinces

Advancing genomics on the blockchain

- Development of region-specific tests where data will be managed on the blockchain
- Combining GTG core technology with blockchain capabilities
- Continuing to work with Blockchain Global to identify new opportunities



2018: Aligning Structure with Strategy

Thank You

Paul Kasian

Chairman and CEO

Email:

paul.kasian@gtglabs.com

Web: www.gtgcorporate.com